Illumina Appoints Mike Bouchard as Vice President of Finance

Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Bouchard as Vice President of Finance. Prior to joining Illumina, Mike served as Vice President of Finance and Accounting for Websense, a global leader in integrated Web, messaging, and data protection technologies. At Websense, Mike was responsible for all financial, accounting, treasury, and tax matters for the company. Before joining Websense, Mike was Director of Finance at Gateway, where he directed the company's annual, quarterly, and long-term planning, forecasting, and budgeting processes. Before his time at Gateway, Mike was the Global Finance Manager for the performance chemicals group at Rohm & Haas Company, where he was responsible for all division financial matters. Previously, Mike was Chief Financial Officer for S.A.L. Limited, a publicly traded company, where he was responsible for accounting, finance, investor relations, and information systems. Mike earned a B.C. from the University of Ottawa, Ontario, and received his MBA from the Richard Ivey School of Business. Mike also qualified as a Chartered Accountant with the Canadian Institute of Chartered Accountants and began his career at Deloitte & Touche working on a variety of audits for large corporations in the manufacturing, banking, investment and captive insurance industries, as well as retail and wholesale companies. In his new position as Illumina’s Vice President of Finance, Mike is responsible for overseeing Illumina’s worldwide finance, accounting, treasury and tax functions. "We are excited to have Mike join Illumina during a time when we are experiencing exponential growth. His finance experience and proven track record of success will help us support our continued worldwide expansion,” said Christian Henry, Illumina’s Senior Vice President and Chief Financial Officer. About Mr. Bouchard’s Compensation The Company granted an option to purchase 75,000 shares of Illumina’s common stock to Mr. Bouchard as part of his inducement to join the company. The option was granted by the Company’s compensation committee pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv) and under Illumina’s New Hire Stock and Incentive Plan, which was approved by Illumina’s Board of Directors on January 29, 2008. This option has the following terms: an exercise price equal to the closing fair market value of Illumina’s common stock on the grant date, a ten-year term and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter. The grant date for this option is March 24, 2008. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. "Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.